PD-L1 Non-Lung (Pembrolizumab), IHC
Test Code
36260
88360
Clinical Significance
PD-L1 Non-Lung (Pembrolizumab), IHC - PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying patients for treatment with KEYTRUDA® (Pembrolizumab). This FDA approved test currently is applicable only to specific tumor types.
For non-FDA approved test indications or sample types, order 94007-PD-L1, IHC with Interpretation.
For other FDA approved primary tumors, please order the following:
For NSCLC order 93279-PD-L1 Lung (Pembrolizumab), IHC, 93359-PD-L1 Lung (Nivolumab), IHC or 94480-PD-L1 Lung (Atezolizumab), IHC; for urothelial bladder carcinoma order 94047-PD-L1 Bladder (Atezolizumab),IHC.
Test Resources
Test FAQ
PD-L1Test Guide
PD-L1: Test Selection GuideTest Details
Methodology
Immunohistochemical Stain
Reference Range(s)
See Laboratory Report
Alternative Name(s)
Keytruda,Dako test PD-L1 IHC 22C3pharmDx™,PDL1,PDL-1
Alternative Specimen(s)
5 (5 micron) unstained charged(+) slides collected in IHC specimen transport kit
Transport Temperature
Room temperature
Setup Schedule, Preferred Specimen(s), Minimum Volume, Collection Instructions, Transport Container, Specimen Stability, Reject Criteria
5 (5 micron) unstained charged(+) slides collected in IHC specimen transport kit
Room temperature